News Shares

Inovio Pharma Shares Rose Today At Close Of Trade


Stocks connected with clinical-stage biotech Inovio Pharmaceuticals (NASDAQ:INO) are up by a wholesome and balanced 20.3%, on abnormally amount that is high as of 10:40 a.m. EDT Tuesday. Today’s double-digit rally seems to be carryover from CEO Dr. Joseph Kim’s presentation during the H.C. Wainwright 22nd Annual internationally Investment Conference yesterday.

While Kim’s presentation didn’t exactly include any earth-shaking updates, he did note that a paper that is peer-reviewed be forthcoming discussing the phase 1 trial outcomes for the business’s closely watched COVID-19 vaccine candidate, INO-4800. This first trial that is human 40 healthy volunteers aged 18 to 50. Previously, Inovio announced that the vaccine produced either antibodies that are neutralizing responses that are t-cell all study individuals.

Inovio’s stocks happen under immense pressure for the last three months. In reality, the drugmaker’s stock has dropped by nearly 60% general to its 52-week high posted straight back June. Investors have backed away from Inovio’s stock mostly as the business has dropped behind the leaders in the hotly contested race to build up a safe and effective vaccine that is COVID-19.

At yesterday’s conference, nonetheless, Kim reported that INO-4800’s planned phase 2/3 test should get clearance from the Food and Drug administration quickly. He additionally noted that he felt “very confident” this pivotal trial would receive external financing — perhaps foreshadowing a large award from Operation Warp Speed in the future that is near. Stocks connected with clinical-stage biotech Inovio Pharmaceuticals.

Should investors purchase into this rally that is latest? Inovio is a biotech that is risky to make sure. But there’s an opportunity that is decent the biotech could indeed land a big award because of its COVID-19 vaccine. So, if you are the risk-tolerant kind, it might pay dividends to get a few shares ahead of this catalyst that is potential.


Billy Houghton

Billy Houghton is a top acclaimed and sought-after commodities futures trading expert. The expertise and in-depth level of analysis that is offered by Billy Houghton is what has managed to put him at the stage of being the top ranked author for MetaNews among multiple different categories. Throughout his career, Billy has specifically spent over three decades on Wall Street fine-tuning his skills, which included over two decades at a trading desk. In more recent times, specifically the last decade, Billy has been researching algorithms of AI in futures trading, and believes they are the future of trading.
Follow Me:

Related Posts